Key facts
- It has raised $35.2M across 1 recorded rounds; the latest was Early Stage VC ($35.2M) in May 2018.
- Notable investors include University of Pittsburgh Innovation Institute.
- ECM Therapeutics has filed 7 Form Ds with the SEC since 2018, most recently May 2024 ($26.1M sold to 138 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ECM Therapeutics
Funding rounds
1 roundsAbout ECM Therapeutics
Developer of extracellular matrix-based regenerative medicines designed to treat esophageal, colorectal, and other medical problems. The company's medicines replace injured or diseased tissues through drug delivery or stem cell therapy using hydrogel technology for expanded, less invasive applications in multiple disease areas to reduce the progression of esophageal cancer and precursor stages that result from gastric reflux, enabling medical researchers to address unmet clinical needs and reduce the multiplication of cancerous cells by minimally invasive endoscopy or by oral administration.
- Sector
- Healthcare
- HQ
- Warrendale, PA, United States
- Founded
- 2017
- Employees
- 9
- Website
- ecmtherapeutics.com/
- Ownership
- Privately Held (backing)
ECM Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ECM Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ECM Therapeutics in its N-PORT filings yet. We sweep new filings monthly.